The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†Glen Lutchman, Jay H. Hoofnagle, Apurva A. Modi et al.|Hepatology|2007Cited by 241
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 studyCynthia Levy, Alexandra Steinberg, Mark G. Swain et al.|Journal of Hepatology|2020Cited by 10
Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 studyGideon M. Hirschfield, DE Jones, Pol Boudes et al.|Journal of Hepatology|2018Cited by 5
Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIESStuart C. Gordon, Marlyn J. Mayo, Palak Trivedi et al.|Gastroenterology|2022Cited by 2
686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDYAndreas E. Kremer, Yun‐Jung Choi, Marlyn J. Mayo et al.|Gastroenterology|2020Cited by 1